Vaginal microbiota and genitourinary syndrome of menopause in premenopausal breast cancer patients receiving endocrine therapy: a longitudinal cohort study protocol - Takeaways - MDSpire

Vaginal microbiota and genitourinary syndrome of menopause in premenopausal breast cancer patients receiving endocrine therapy: a longitudinal cohort study protocol

  • By

  • Fangfang Chen

  • Zhiyuan Bo

  • Yangfan Fan

  • Yizhou Huang

  • Yiding Chen

  • Fang Wan

  • June 15, 2026

  • 0 min

Share

  • 1

    Endocrine therapy for hormone receptor-positive breast cancer in premenopausal women often induces genitourinary syndrome of menopause (GSM) due to hypoestrogenism.

  • 2

    The study aims to assess the effects of endocrine therapy on vaginal microbiome diversity and dominant taxa in breast cancer survivors.

  • 3

    A total of 110 premenopausal women will be enrolled and allocated to receive either ovarian function suppression with aromatase inhibitors or tamoxifen.

  • 4

    Vaginal swabs will be collected at multiple time points for microbiome analysis, alongside assessments of GSM symptoms and vaginal health.

  • 5

    The study seeks to reveal mechanisms of GSM and inform personalized interventions through the integration of molecular and clinical data.

Original Source(s)

Vaginal microbiota and genitourinary syndrome of menopause in premenopausal breast cancer patients receiving endocrine therapy: a longitudinal cohort study protocol

  • by Fangfang Chen, Zhiyuan Bo, Yangfan Fan, Yizhou Huang, Yiding Chen, Fang Wan

  • June 15, 2026

Related Content

A prediction model and risk stratification tool for survival by chemotherapy in invasive micropapillary carcinoma of the breast: a population-based study with external validation

Global research trends of TCM-based nonpharmacologic interventions in breast cancer supportive care: a bibliometric analysis (2000–2025)

The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics